Healthy
Conditions
Brief summary
The main purpose of this study is to learn more about how the drug is absorbed in to the blood stream and how it is eliminated from the body. The safety and tolerability of LY3526318 will also be evaluated when given by mouth either by single or multiple doses to healthy participants. The study will have two parts. Each participant will enroll in only one part. For each participant, Part A will last up to 44 days and Part B will last up to 50 days, including screening and follow-up.
Interventions
DRUGLY3526318
Administered orally.
DRUGPlacebo
Administered orally.
Sponsors
Eli Lilly and Company
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Are overtly healthy males or females, as determined through medical history and physical examination * Have a body mass index (BMI) between 18 and 32 kilograms per square meter (kg/m²) * Have clinical laboratory test results within normal reference range
Exclusion criteria
* Have a history or presence of medical illness including, but not limited to, cardiovascular, hepatic, respiratory, hematological, endocrine, psychiatric or neurological disease, convulsions, or any clinically significant laboratory abnormality * Have an abnormality in the 12-lead electrocardiogram (ECG) * Have a history of clinically significant multiple or severe drug allergies * Show evidence of human immunodeficiency virus (HIV) and/or positive human HIV antibodies, hepatitis C and/or positive hepatitis C antibody, or hepatitis B and/or positive hepatitis B surface antigen. * Have an abnormal blood pressure * Have received treatment with biologic agents (such as monoclonal antibodies, including marketed drugs) within 3 months or 5 half-lives (whichever is longer) * Are unwilling to stop herbal supplements, over the counter or prescription medicines * Are currently enrolled in a clinical drug study or any other type of medical research judged not to be scientifically or medically compatible with this study. * Participants with a history of drug abuse
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Part A - SAD, Pharmacokinetics (PK): Area Under the Concentration Time Curve From Time 0 to Infinity (AUC 0-∞) of LY3526318 | Predose,1, 2, 4, 6, 8,12, 24, 48, 72, 96 hours post-dose | Area Under the Concentration Time Curve From Time 0 to Infinity (AUC 0-∞) of LY3526318 |
| Part A - SAD, PK: Maximum Observed Drug Concentration (Cmax) of LY3526318 | Predose,1, 2, 4, 6, 8,12, 24, 48, 72, 96 hours post-dose | Part A - SAD, PK: Maximum Observed Drug Concentration (Cmax) of LY3526318 |
| Part B - MAD, PK: Area Under the Concentration Time Curve From Time Zero to the End of the Dosing Interval, Tau (AUC[0-tau ]) of LY3526318 | Day 5: Predose,1, 2, 4, 6, 8,12, 24 hours post dose | Part B - MAD, PK: Area Under the Concentration Time Curve From Time Zero to the End of the Dosing Interval, Tau (AUC\[0-tau \]) of LY3526318 |
| Part B - MAD, PK: Maximum Observed Drug Concentration (Cmax) of LY3526318 | Day 5: Predose,1, 2, 4, 6, 8,12, 24 hours post dose | Part B - MAD, PK: Maximum Observed Drug Concentration (Cmax) of LY3526318 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Part A, SAD: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Single oral dose to up to 11 days of follow-up | A TEAE started on or after the date and time of the first dose of study drug administered in this study, or started prior to the study drug administration but worsened after the study drug started. Clinically significant events were defined as SAEs and other non-serious adverse events (AEs). A summary of SAEs and other non-serious AEs is located in the Reported Adverse Events module. |
| Part A, Effect of a Meal on Pharmacokinetics of LY3526318: Time at Maximal Concentration (Tmax) | Predose,1, 2, 4, 6, 8,12, 24, 48, 72, 96 hours post-dose | Part A, Effect of a Meal on Pharmacokinetics of LY3526318: Time at Maximal Concentration (Tmax) |
| Part B, MAD: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Up to 14 days following first dose | A TEAE started on or after the date and time of the first dose of study drug administered in this study, or started prior to the study drug administration but worsened after the study drug started. Clinically significant events were defined as SAEs and other non-serious adverse events (AEs). A summary of SAEs and other non-serious AEs is located in the Reported Adverse Events module. |
| Part A, Effect of a Meal on Pharmacokinetics of LY3526318: Maximum Concentration (Cmax) | Predose,1, 2, 4, 6, 8,12, 24, 48, 72, 96 hours post-dose | Part A, Effect of a meal on pharmacokinetics of LY3526318: Maximum Concentration (Cmax) |
| Part A, Effect of a Meal on Pharmacokinetics of LY3526318: Area Under the Concentration Time Curve From Time 0 to Infinity (AUC 0-∞) | Predose,1, 2, 4, 6, 8,12, 24, 48, 72, 96 hours post-dose | Part A, Effect of a meal on pharmacokinetics of LY3526318: Area under the concentration time curve from time 0 to infinity (AUC 0-∞) |
Countries
Netherlands
Participant flow
Pre-assignment details
This study consists of 2 parts: * Part A: Single-ascending dose (SAD, \[including a food effect (FE)\]). * Part B: Multiple-ascending dose (MAD), \[including a food effect (FE)\]). Both parts were randomized, double-blind, and placebo-controlled.
Participants by arm
| Arm | Count |
|---|---|
| Part A SAD: Sequence P1-L2-L3-L4 P1: Participants received placebo administered orally under fasted condition during period 1.
L2: Participants received 250 mg LY3526318 administered orally under fasted condition during period 2.
L3: Participants received 250 mg LY3526318 administered orally in fed state after a light breakfast during period 3.
L4: Participants received 250 mg LY3526318 administered orally in fed state after a high-fat breakfast during period 4. | 2 |
| Part A SAD: L1-P1-L3-L4 L1: Participants received 100 mg LY3526318 administered orally under fasted condition during period 1.
P1: Participants received placebo administered orally under fasted condition during period 2.
L3: Participants received 250 mg LY3526318 administered orally in fed state after a light breakfast during period 3.
L4: Participants received 250 mg LY3526318 administered orally in fed state after a high-fat breakfast during period 4. | 2 |
| Part A SAD: L1-L2-P3-L4 L1: Participants received 100 mg LY3526318 administered orally under fasted condition during period 1.
L2: Participants received 250 mg LY3526318 administered orally under fasted conditions during period 2.
P3: Participants received placebo administered orally in fed state after a light breakfast during period 3.
L4: Participants received 250 mg LY3526318 administered orally in fed state after a high-fat breakfast during period 4. | 2 |
| Part A: L1-L2-L3-P4 L1: Participants received 100 mg LY3526318 administered orally under fasted condition during period 1 L2: Participants received 250 mg LY3526318 administered orally under fasted condition during period 2.
L3: Participants received 250 mg LY3526318 administered orally in fed state after a light breakfast during period 3.
P4: Participants received placebo administered orally in fed state after a high-fat breakfast during period 4. | 2 |
| Part B MAD: Placebo Participants received placebo administered orally under fasted conditions on Day 1 and Day 5 and in fed state after participants ate a standard breakfast without respect to dosing time on Day 2 to Day 4 | 2 |
| Part B MAD: 250 mg LY3526318 Participants received 250 mg LY3526318 administered orally under fasted conditions on Day 1 and Day 5 and in fed state after participants ate a standard breakfast without respect to dosing time on Day 2 to Day 4. | 6 |
| Total | 16 |
Baseline characteristics
| Characteristic | Part A SAD: Sequence P1-L2-L3-L4 | Total | Part B MAD: 250 mg LY3526318 | Part B MAD: Placebo | Part A: L1-L2-L3-P4 | Part A SAD: L1-L2-P3-L4 | Part A SAD: L1-P1-L3-L4 |
|---|---|---|---|---|---|---|---|
| Age, Continuous | 52 years STANDARD_DEVIATION 4 | 40 years STANDARD_DEVIATION 16.57 | 35 years STANDARD_DEVIATION 21 | 31 years STANDARD_DEVIATION 14 | 43 years STANDARD_DEVIATION 13 | 59 years STANDARD_DEVIATION 3 | 31 years STANDARD_DEVIATION 11 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 2 Participants | 15 Participants | 6 Participants | 2 Participants | 2 Participants | 1 Participants | 2 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 2 Participants | 13 Participants | 6 Participants | 1 Participants | 2 Participants | 1 Participants | 1 Participants |
| Region of Enrollment Netherlands | 2 Participants | 16 Participants | 6 Participants | 2 Participants | 2 Participants | 2 Participants | 2 Participants |
| Sex: Female, Male Female | 1 Participants | 10 Participants | 4 Participants | 2 Participants | 1 Participants | 1 Participants | 1 Participants |
| Sex: Female, Male Male | 1 Participants | 6 Participants | 2 Participants | 0 Participants | 1 Participants | 1 Participants | 1 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 2 | 0 / 2 | 0 / 4 | 0 / 6 | 0 / 6 | 0 / 6 | 0 / 6 | 0 / 2 | 0 / 6 |
| other Total, other adverse events | 1 / 2 | 1 / 2 | 2 / 4 | 4 / 6 | 1 / 6 | 2 / 6 | 2 / 6 | 1 / 2 | 4 / 6 |
| serious Total, serious adverse events | 0 / 2 | 0 / 2 | 0 / 4 | 0 / 6 | 0 / 6 | 0 / 6 | 0 / 6 | 0 / 2 | 0 / 6 |
Outcome results
Primary
Part A - SAD, Pharmacokinetics (PK): Area Under the Concentration Time Curve From Time 0 to Infinity (AUC 0-∞) of LY3526318
Area Under the Concentration Time Curve From Time 0 to Infinity (AUC 0-∞) of LY3526318
Time frame: Predose,1, 2, 4, 6, 8,12, 24, 48, 72, 96 hours post-dose
Population: Part A - SAD: All participants who received at least one dose of study drug and had evaluable PK data.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Part A - SAD: 250 mg LY3526318 Fed (Light Breakfast) | Part A - SAD, Pharmacokinetics (PK): Area Under the Concentration Time Curve From Time 0 to Infinity (AUC 0-∞) of LY3526318 | 147978 nanograms*hours per milliliter (ng*h/mL) | Geometric Coefficient of Variation 37.5 |
| Part A - SAD: 250 mg LY3526318 Fed (High Fat Meal) | Part A - SAD, Pharmacokinetics (PK): Area Under the Concentration Time Curve From Time 0 to Infinity (AUC 0-∞) of LY3526318 | 131271 nanograms*hours per milliliter (ng*h/mL) | Geometric Coefficient of Variation 61.8 |
| Part A - SAD: 250 mg LY3526318 Fasted | Part A - SAD, Pharmacokinetics (PK): Area Under the Concentration Time Curve From Time 0 to Infinity (AUC 0-∞) of LY3526318 | 137814 nanograms*hours per milliliter (ng*h/mL) | Geometric Coefficient of Variation 58.6 |
| Part A - SAD: 100 mg LY3526318 Fasted | Part A - SAD, Pharmacokinetics (PK): Area Under the Concentration Time Curve From Time 0 to Infinity (AUC 0-∞) of LY3526318 | 76902 nanograms*hours per milliliter (ng*h/mL) | Geometric Coefficient of Variation 56.1 |
Primary
Part A - SAD, PK: Maximum Observed Drug Concentration (Cmax) of LY3526318
Part A - SAD, PK: Maximum Observed Drug Concentration (Cmax) of LY3526318
Time frame: Predose,1, 2, 4, 6, 8,12, 24, 48, 72, 96 hours post-dose
Population: Part A - SAD: All participants who received at least one dose of study drug and had evaluable PK data.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Part A - SAD: 250 mg LY3526318 Fed (Light Breakfast) | Part A - SAD, PK: Maximum Observed Drug Concentration (Cmax) of LY3526318 | 12406 nanograms per milliliter (ng/mL) | Geometric Coefficient of Variation 26.4 |
| Part A - SAD: 250 mg LY3526318 Fed (High Fat Meal) | Part A - SAD, PK: Maximum Observed Drug Concentration (Cmax) of LY3526318 | 6199 nanograms per milliliter (ng/mL) | Geometric Coefficient of Variation 61.4 |
| Part A - SAD: 250 mg LY3526318 Fasted | Part A - SAD, PK: Maximum Observed Drug Concentration (Cmax) of LY3526318 | 9544 nanograms per milliliter (ng/mL) | Geometric Coefficient of Variation 26.8 |
| Part A - SAD: 100 mg LY3526318 Fasted | Part A - SAD, PK: Maximum Observed Drug Concentration (Cmax) of LY3526318 | 5441 nanograms per milliliter (ng/mL) | Geometric Coefficient of Variation 49.9 |
Primary
Part B - MAD, PK: Area Under the Concentration Time Curve From Time Zero to the End of the Dosing Interval, Tau (AUC[0-tau ]) of LY3526318
Part B - MAD, PK: Area Under the Concentration Time Curve From Time Zero to the End of the Dosing Interval, Tau (AUC\[0-tau \]) of LY3526318
Time frame: Day 5: Predose,1, 2, 4, 6, 8,12, 24 hours post dose
Population: Part B - MAD: All participants who received at least one dose of study drug and had evaluable PK data.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Part A - SAD: 250 mg LY3526318 Fed (Light Breakfast) | Part B - MAD, PK: Area Under the Concentration Time Curve From Time Zero to the End of the Dosing Interval, Tau (AUC[0-tau ]) of LY3526318 | 89614 ng*h/mL | Geometric Coefficient of Variation 19.7 |
Primary
Part B - MAD, PK: Maximum Observed Drug Concentration (Cmax) of LY3526318
Part B - MAD, PK: Maximum Observed Drug Concentration (Cmax) of LY3526318
Time frame: Day 5: Predose,1, 2, 4, 6, 8,12, 24 hours post dose
Population: Part B - MAD: All participants who received at least one dose of study drug and had evaluable PK data.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Part A - SAD: 250 mg LY3526318 Fed (Light Breakfast) | Part B - MAD, PK: Maximum Observed Drug Concentration (Cmax) of LY3526318 | 10717 nanograms per milliliter (ng/mL) | Geometric Coefficient of Variation 35.1 |
Secondary
Part A, Effect of a Meal on Pharmacokinetics of LY3526318: Area Under the Concentration Time Curve From Time 0 to Infinity (AUC 0-∞)
Part A, Effect of a meal on pharmacokinetics of LY3526318: Area under the concentration time curve from time 0 to infinity (AUC 0-∞)
Time frame: Predose,1, 2, 4, 6, 8,12, 24, 48, 72, 96 hours post-dose
Population: Part A, SAD: All participants who received 250 mg LY3526318 and had evaluable PK data.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Part A - SAD: 250 mg LY3526318 Fed (Light Breakfast) | Part A, Effect of a Meal on Pharmacokinetics of LY3526318: Area Under the Concentration Time Curve From Time 0 to Infinity (AUC 0-∞) | Ratio of Fed Light Breakfast/ Fasted | 1.1341 unitless |
| Part A - SAD: 250 mg LY3526318 Fed (Light Breakfast) | Part A, Effect of a Meal on Pharmacokinetics of LY3526318: Area Under the Concentration Time Curve From Time 0 to Infinity (AUC 0-∞) | Ratio of Fed High Fat Meal/ Fasted | 0.8454 unitless |
Secondary
Part A, Effect of a Meal on Pharmacokinetics of LY3526318: Maximum Concentration (Cmax)
Part A, Effect of a meal on pharmacokinetics of LY3526318: Maximum Concentration (Cmax)
Time frame: Predose,1, 2, 4, 6, 8,12, 24, 48, 72, 96 hours post-dose
Population: Part A, SAD: All participants who received 250 mg LY3526318 and had evaluable PK data.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Part A - SAD: 250 mg LY3526318 Fed (Light Breakfast) | Part A, Effect of a Meal on Pharmacokinetics of LY3526318: Maximum Concentration (Cmax) | Ratio of Fed Light Breakfast/ Fasted | 1.2768 unitless |
| Part A - SAD: 250 mg LY3526318 Fed (Light Breakfast) | Part A, Effect of a Meal on Pharmacokinetics of LY3526318: Maximum Concentration (Cmax) | Ratio of Fed High Fat Meal/ Fasted | 0.6195 unitless |
Secondary
Part A, Effect of a Meal on Pharmacokinetics of LY3526318: Time at Maximal Concentration (Tmax)
Part A, Effect of a Meal on Pharmacokinetics of LY3526318: Time at Maximal Concentration (Tmax)
Time frame: Predose,1, 2, 4, 6, 8,12, 24, 48, 72, 96 hours post-dose
Population: Part A, SAD: All participants who received 250 mg LY3526318 and had evaluable PK data
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Part A - SAD: 250 mg LY3526318 Fed (Light Breakfast) | Part A, Effect of a Meal on Pharmacokinetics of LY3526318: Time at Maximal Concentration (Tmax) | Fed Light Breakfast - Fasted | 0.00 hours |
| Part A - SAD: 250 mg LY3526318 Fed (Light Breakfast) | Part A, Effect of a Meal on Pharmacokinetics of LY3526318: Time at Maximal Concentration (Tmax) | Fed High Fat Meal - Fasted | 0.03 hours |
Secondary
Part A, SAD: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
A TEAE started on or after the date and time of the first dose of study drug administered in this study, or started prior to the study drug administration but worsened after the study drug started. Clinically significant events were defined as SAEs and other non-serious adverse events (AEs). A summary of SAEs and other non-serious AEs is located in the Reported Adverse Events module.
Time frame: Single oral dose to up to 11 days of follow-up
Population: Part A, SAD: All participants who received at least one dose of study drug.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part A - SAD: 250 mg LY3526318 Fed (Light Breakfast) | Part A, SAD: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | TEAEs | 2 Participants |
| Part A - SAD: 250 mg LY3526318 Fed (Light Breakfast) | Part A, SAD: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | SAEs | 0 Participants |
| Part A - SAD: 250 mg LY3526318 Fed (High Fat Meal) | Part A, SAD: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | TEAEs | 1 Participants |
| Part A - SAD: 250 mg LY3526318 Fed (High Fat Meal) | Part A, SAD: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | SAEs | 0 Participants |
| Part A - SAD: 250 mg LY3526318 Fasted | Part A, SAD: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | TEAEs | 1 Participants |
| Part A - SAD: 250 mg LY3526318 Fasted | Part A, SAD: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | SAEs | 0 Participants |
| Part A - SAD: 100 mg LY3526318 Fasted | Part A, SAD: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | TEAEs | 2 Participants |
| Part A - SAD: 100 mg LY3526318 Fasted | Part A, SAD: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | SAEs | 0 Participants |
| Part A - SAD: 250 mg LY3526318 Fasted | Part A, SAD: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | SAEs | 0 Participants |
| Part A - SAD: 250 mg LY3526318 Fasted | Part A, SAD: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | TEAEs | 2 Participants |
| Part A - SAD: 250 mg LY3526318 Fed (Light Breakfast) | Part A, SAD: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | TEAEs | 4 Participants |
| Part A - SAD: 250 mg LY3526318 Fed (Light Breakfast) | Part A, SAD: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | SAEs | 0 Participants |
| Part A - SAD: 250 mg LY3526318 Fed (High Fat Meal) | Part A, SAD: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | SAEs | 0 Participants |
| Part A - SAD: 250 mg LY3526318 Fed (High Fat Meal) | Part A, SAD: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | TEAEs | 1 Participants |
Secondary
Part B, MAD: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
A TEAE started on or after the date and time of the first dose of study drug administered in this study, or started prior to the study drug administration but worsened after the study drug started. Clinically significant events were defined as SAEs and other non-serious adverse events (AEs). A summary of SAEs and other non-serious AEs is located in the Reported Adverse Events module.
Time frame: Up to 14 days following first dose
Population: Part B, MAD: All participants who received at least one dose of study drug.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part A - SAD: 250 mg LY3526318 Fed (Light Breakfast) | Part B, MAD: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | TEAEs | 1 Participants |
| Part A - SAD: 250 mg LY3526318 Fed (Light Breakfast) | Part B, MAD: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | SAEs | 0 Participants |
| Part A - SAD: 250 mg LY3526318 Fed (High Fat Meal) | Part B, MAD: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | TEAEs | 4 Participants |
| Part A - SAD: 250 mg LY3526318 Fed (High Fat Meal) | Part B, MAD: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | SAEs | 0 Participants |